Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease.

Maezawa I, Jenkins DP, Jin BE, Wulff H.

Int J Alzheimers Dis. 2012;2012:868972. doi: 10.1155/2012/868972. Epub 2012 May 22.

2.

Ion channels on microglia: therapeutic targets for neuroprotection.

Skaper SD.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):44-56. Review.

PMID:
21143139
3.
5.

Inhibition of the Ca²⁺-dependent K⁺ channel, KCNN4/KCa3.1, improves tissue protection and locomotor recovery after spinal cord injury.

Bouhy D, Ghasemlou N, Lively S, Redensek A, Rathore KI, Schlichter LC, David S.

J Neurosci. 2011 Nov 9;31(45):16298-308. doi: 10.1523/JNEUROSCI.0047-11.2011.

6.

Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications.

Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V.

Curr Med Chem. 2007;14(13):1437-57. Review.

PMID:
17584055
7.
8.

IL-4 type 1 receptor signaling up-regulates KCNN4 expression, and increases the KCa3.1 current and its contribution to migration of alternative-activated microglia.

Ferreira R, Lively S, Schlichter LC.

Front Cell Neurosci. 2014 Jul 1;8:183. doi: 10.3389/fncel.2014.00183. eCollection 2014.

10.

Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.

Walker D, Lue LF.

Curr Neuropharmacol. 2007 Dec;5(4):232-43. doi: 10.2174/157015907782793667.

11.

Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?

Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A.

Int Rev Neurobiol. 2007;82:235-46. Review.

PMID:
17678964
12.

Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease.

Shie FS, Woltjer RL.

Curr Med Chem. 2007;14(27):2865-71. Review.

PMID:
18045132
13.

Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms.

Halliday G, Robinson SR, Shepherd C, Kril J.

Clin Exp Pharmacol Physiol. 2000 Jan-Feb;27(1-2):1-8. Review.

PMID:
10696521
14.
16.

Microglial phagocytosis induced by fibrillar β-amyloid is attenuated by oligomeric β-amyloid: implications for Alzheimer's disease.

Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, Chen XC.

Mol Neurodegener. 2011 Jun 30;6:45. doi: 10.1186/1750-1326-6-45.

17.

Amyloid-β-induced reactive oxygen species production and priming are differentially regulated by ion channels in microglia.

Schilling T, Eder C.

J Cell Physiol. 2011 Dec;226(12):3295-302. doi: 10.1002/jcp.22675.

PMID:
21321937
18.

KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages.

Grimaldi A, D'Alessandro G, Golia MT, Grössinger EM, Di Angelantonio S, Ragozzino D, Santoro A, Esposito V, Wulff H, Catalano M, Limatola C.

Cell Death Dis. 2016 Apr 7;7:e2174. doi: 10.1038/cddis.2016.73.

19.

Minocycline does not affect amyloid beta phagocytosis by human microglial cells.

Familian A, Eikelenboom P, Veerhuis R.

Neurosci Lett. 2007 Apr 6;416(1):87-91. Epub 2007 Jan 27.

PMID:
17317005
20.

The biphasic role of microglia in Alzheimer's disease.

Mizuno T.

Int J Alzheimers Dis. 2012;2012:737846. doi: 10.1155/2012/737846. Epub 2012 May 10.

Items per page

Supplemental Content

Write to the Help Desk